Table q1_q4_2021_prescription_drug_wac

Table: q1_q4_2021_prescription_drug_wac_increases , manufacturer_name like L*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000083	Laboratoire HRA Pharma	03/31/2021	76336008060	Lysodren 500 mg tablets 100 count bottles	02/15/2021	91.29	1013.39	None	Single Source Drug	None	1	None	1	None	1	03/15/2018	BMS	None	1	None	479.95	479.95	1970	89.95	None	Lysodren US rights acquired from BMS in March 2018. NDC changed from BMS to HRA Pharma in May 2019. Acquisition price is non-public information. WAC at acquisition from BMS in 2018 was $479.95. Introduced to market in 1970.
Rx0000083	Laboratoire HRA Pharma	03/31/2021	76336045518	Metopirone 250 mg capsules 18 count bottles	02/15/2021	52.22	579.72	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Metopirone sales and unit sales are non-public information. The product was acquired from Novartis in March 2011. The WAC at time of acquisition is unknown (2011). The product was introduced to the US in 1961.
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2021	11994001104	Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, one box four (4) vials	01/01/2021	63.75	1126.27	03/16/2037	Single Source Drug	None	1	Increases are due to costs relating to raw material and labor expenses necessary for the manufacture and delivery of our Products.	None	None	None	None	None	None	None	None	None	None	None	None	None	Not Applicable. This product was not acquired.
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2021	11994001116	Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, one box sixteen (16) vials	01/01/2021	255.00	4505.06	03/16/2037	Single Source Drug	None	1	Increases are due to costs relating to raw material and labor expenses necessary for the manufacture and delivery of our Products.	None	None	None	None	None	None	None	None	None	None	None	None	None	Not Applicable. This product was not acquired.
Rx0000317	LEADING PHARMA, LLC	06/30/2021	69315023203	AMINOCAPROIC ACID 1000MG TABS 30	06/21/2021	294.65	1008.11	None	Non-innovator Multiple Source Drug	16142522	None	Matching competitor	None	Remain competative	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000276	LEO Pharma Inc.	03/31/2021	50222030260	ENSTILAR AEROSOL FOAM, 1 CAN 60gm 0.005-0.064 %	01/01/2021	55.67	1168.95	12/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products.
Rx0000276	LEO Pharma Inc.	03/31/2021	50222030266	ENSTILAR AEROSOL FOAM, 2 CANS 120 gm 0.005-0.064 %	01/01/2021	111.32	2337.88	12/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products.
Rx0000276	LEO Pharma Inc.	03/31/2021	50222030350	FINACEA 15% FOAM 50GM CAN	01/01/2021	18.28	383.84	02/28/2029	Single Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	326.89	297.44	2015	255.01	None	Market WAC effective 08/31/2015. We are reporting this NDC because it replaced the Bayer NDC 50419082901. The LEO NDC 50222030350 shares the same history as the Bayer NDC 50419082901. The market entry date for this LEO NDC 50222030350 was April 2020. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products.
Rx0000276	LEO Pharma Inc.	03/31/2021	50419082901	FINACEA 15% FOAM 50GM CN	01/01/2021	18.28	383.84	02/28/2029	Single Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	326.89	297.44	2015	255.01	None	Market WAC effective 08/31/2015. Bayer NDC 50419082901 was replaced by LEO NDC 50222030350. LEO NDC 50222030350 entered market in April 2020 and uses the same history as Bayer NDC 50419082901. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products.
Rx0000276	LEO Pharma Inc.	03/31/2021	50222050166	TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 120g	01/01/2021	66.79	2293.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products.
Rx0000276	LEO Pharma Inc.	03/31/2021	50222050106	TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 60g	01/01/2021	33.40	1146.68	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products.
Rx0000025	Lundbeck LLC	03/31/2021	67386082019	Northera 100mg. 90 Capsules	01/04/2021	265.92	3065.13	02/18/2021	Single Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386082119	Northera 200mg. 90 Capsules	01/04/2021	531.85	6130.25	02/18/2021	Single Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386082219	Northera 300mg. 90 Capsules	01/04/2021	797.77	9195.39	02/18/2021	Single Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386031401	Onfi 10mg. 100 Tablets	01/04/2021	209.27	2412.13	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386031501	Onfi 20mg. 100 Tablets	01/04/2021	418.54	4824.21	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386031321	Onfi Oral Suspension 2.5mg/mL 120mL Bottle	01/04/2021	109.95	1267.35	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386011101	Sabril 500mg. 100 Tablets	01/04/2021	1519.98	17519.82	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386021165	Sabril 500mg. 50 Packets 500mg. each	01/04/2021	759.99	8759.92	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386042101	Xenazine 12.5mg. 112 Tablets	01/04/2021	1466.68	16905.40	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2021	67386042201	Xenazine 25.0mg. 112 Tablets	01/04/2021	2933.36	33810.81	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.